Oncostatin M
Oncostatin M Molekülinformation
| Englischer Name | Oncostatin M | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 0 | Target-Alias | Oncostatin-M，OSM，Oncostatin M，MGC20461 |
| Höchste Forschungs- und Entwicklungsphase | Discontinued | ||
| Englischer Name | Oncostatin M |
| Target-Alias | Oncostatin-M，OSM，Oncostatin M，MGC20461 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 0 |
| Höchste Forschungs- und Entwicklungsphase | Discontinued |
Oncostatin M Produktliste
- Attribut
Protein (3)
- Produktbibliothek
Online (3)
- Spezies
Human (3)
- Etikett
Tag Free (2)His Tag & Avi Tag (1)
- Marker
Unconjugated (2)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human Oncostatin M (OSM) Protein, premium grade |  |  |  |  In den Warenkorb legen | |
| Human | HEK293 | Human Oncostatin M (OSM) (26-221) Protein, premium grade |  | |  | In den Warenkorb legen | |
| Human | HEK293 | Biotinylated Human Oncostatin M (OSM) Protein, Avitag™,His Tag |  | | | In den Warenkorb legen |
Gesamtmenge3
- 1
Oncostatin M Molekülhintergrund
Oncostatin M (OSM) serves as a critical maturation factor during the definitive endoderm-to-hepatocyte differentiation of human iPSCs/ESCs. Applied at the hepatoblast-to-hepatocyte transition stage—typically together with HGF and dexamethasone—OSM activates the gp130/LIFRβ receptor complex and downstream JAK/STAT3 and MAPK pathways. This drives robust upregulation of mature hepatic markers including ALB, major CYP enzymes (e.g., CYP3A4, CYP1A2), and bile acid transporters, thereby conferring drug-metabolizing, albumin-secreting, and detoxification capacities essential for functional hepatocyte-like cells and liver organoid models.
Oncostatin M Molekülalias
OSM,MGC20461,Oncostatin M
- Molekülinformation
- Produktliste